Aclaris Therapeutics reports ‘positive’ results from Phase 1a trial of ATI-052

Aclaris Therapeutics (ACRS) announced positive interim results from the first-in-human Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4Ralpha bispecific antibody ATI-052. “Aclaris has experienced significant momentum across our pipeline over the past few months; consistent with that strong momentum, we are pleased to report positive interim results from our Phase 1a SAD/MAD trial of ATI-052 that exceeded our expectations,” said Dr. Neal Walker, Chief Executive Officer of Aclaris. “ATI-052 demonstrated a strong safety and tolerability profile, dose proportional pharmacokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose – all of which support its best-in-class potential in a variety of inflammatory and immunological diseases due to its ability to uniquely impact multiple pathways of inflammation.”